Composition for ischemic bowel disease and application thereof

通过组合物阿魏酸、藁本内酯、欧当归内酯A、龙胆苦苷、獐芽菜苦苷、当药苷和马钱苷酸的使用,解决了缺血性肠病治疗难题, It significantly improves intestinal mucosa and vascular health, inhibits adhesions, and achieves effective treatment of ischemic intestinal disease.

CN118903168AActive Publication Date: 2024-11-08FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202410879629.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-08
Estimated Expiration
2044-07-02

AI Technical Summary

Technical Problem

The existing technology for the treatment of ischemic bowel disease is difficult to effectively solve, especially because reperfusion injury increases the difficulty of treatment, and the complex pathological mechanism lacks ideal treatment measures.

Method used

Provided is a composition including ferulic acid, oxolactone, oleracide A, gentian chorizoside, gentian chorizoside, gentian chorizoside and equinocrinol, which protects vascular endothelial cells and reduces vascular access. Permeability, alleviate intestinal epithelial damage, maintain intestinal barrier function, and inhibit abnormal proliferation of fibroblasts, and is used to treat ischemic enteropathy.

Benefits of technology

The composition significantly improves intestinal mucosa atrophy, reduces inflammatory infiltration, improves vascular permeability, and inhibits collagen deposition in adhesion tissue. Multiple components and multiple pathways work together to treat ischemic enteropathy, and the efficacy is better than that of a single compound.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004924112790000041
    Figure BDA0004924112790000041
  • Figure BDA0004924112790000051
    Figure BDA0004924112790000051
  • Figure BDA0004924112790000061
    Figure BDA0004924112790000061
Patent Text Reader

Abstract

The invention discloses a composition for ischemic bowel disease and application thereof, and relates to the technical field of medicine preparation. The composition is prepared from ferulic acid, ligustilide, levistilide A, gentiopicroside, swertiamarin, swertiamarin and loganic acid. According to the composition for treating the ischemic bowel disease, disclosed by the invention, the vascular permeability can be improved, the intestinal barrier function can be maintained and the deposition of collagen can be inhibited by regulating and controlling FAK / VE-cadherin, MLCK / MLC and TGF-beta1 / SMAD3 pathways, so that the effect of treating the ischemic bowel disease is jointly exerted by multiple components and multiple pathways. The invention solves the problem of lack of medicine for treating ischemic bowel disease in the prior art.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug preparation, and in particular to a composition for ischemic bowel disease and application thereof. Background Art

[0002] Ischemic bowel disease is a disease in which insufficient blood supply to the intestine leads to local intestinal tissue necrosis or even infarction. With the increasing aging of the population in recent years, the incidence and mortality of ischemic bowel disease are still increasing year by year, and it is an important clinical problem that needs to be urgently addressed.

[0003] Clinically, surgery, thrombolysis and intervention are often used to restore blood supply as soon as possible. However, this will lead to more severe reperfusion injury, increasing the difficulty of treating the disease. The causes of ischemic bowel disease involve acute and chronic mesenteric ischemia, vascular obstructive and non-obstructive ischemia, etc. The pathological mechanism is complex and there is currently no ideal treatment measure. Therefore, there is an urgent need for a drug to treat ischemic bowel disease. Summary of the invention

[0004] In order to solve the above technical problems, the purpose of the present invention is to provide a composition for ischemic bowel disease and its application, so as to solve the problem of lack of drugs for treating ischemic bowel disease.

[0005] The technical solution of the present invention to solve the above technical problems is as follows: a composition for ischemic bowel disease is provided, comprising ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariae maricoside, gentioside and loganinic acid.

[0006] The beneficial effects of the present invention are as follows: the composition is derived from the traditional Chinese medicines Gentiana macrophylla and Ligusticum chuanxiong, and the composition of the present invention has significant therapeutic effects compared with a single compound. The composition can protect vascular endothelial cells to reduce vascular permeability, reduce intestinal epithelial damage to maintain intestinal barrier function, and inhibit abnormal proliferation of fibroblasts to reduce intestinal adhesion, thereby showing the efficacy of treating ischemic bowel disease.

[0007] On the basis of the above technical solution, the present invention can also be improved as follows:

[0008] Furthermore, the molar ratio of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, tangyroxylin and loganinic acid is 0.1-5: 0.1-5: 0.1-20: 0.1-5: 0.1-5: 0.1-5: 0.1-5: 0.1-5.

[0009] Furthermore, the molar ratio of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, angonic acid and loganinic acid is 5:1:1:5:1:1:5.

[0010] Furthermore, the molar ratio of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, angonic acid and loganinic acid is 1:1:1:1:1:1:1:1.

[0011] The present invention also provides application of the above composition in preparing medicine for ischemic bowel disease.

[0012] Further, ischemic bowel disease includes acute mesenteric ischemia, chronic mesenteric ischemia and ischemic colitis.

[0013] The present invention also provides a medicine for ischemic bowel disease, comprising the above composition for ischemic bowel disease.

[0014] Furthermore, the dosage form of the drug is injection, powder, pill, tablet, microcapsule, soft capsule, film, ointment, tincture, granule, and aerosol permitted in pharmaceutical science.

[0015] The present invention has the following beneficial effects:

[0016] 1. The composition of the present invention can improve intestinal mucosal atrophy and shedding of intestinal villi, reduce inflammatory infiltration of intestinal epithelial cells, and maintain intestinal barrier function through the MLCK / MLC pathway based on intestinal epithelial cells.

[0017] 2. The composition of the present invention can reduce endothelial cell damage and improve intestinal vascular permeability through the FAK / VE-cadherin pathway based on endothelial cells.

[0018] 3. The composition of the present invention can reduce intestinal adhesion and inhibit the distribution and deposition of collagen in adhesion tissue through the TGF-β1 / SMAD3 pathway based on fibroblasts.

[0019] 4. The composition for ischemic bowel disease of the present invention can improve vascular permeability, maintain intestinal barrier function and inhibit collagen deposition by regulating FAK / VE-cadherin, MLCK / MLC and TGF-β1 / SMAD3 pathways, thereby exerting the efficacy of treating ischemic bowel disease through multiple components and multiple pathways.

[0020] 5. The composition of the present invention can be used in different proportions to prepare injections, powders, pills, tablets, microcapsules, soft capsules, films, ointments, tinctures, granules, or aerosols for clinical use. Multiple components and multiple targets can work together to treat ischemic bowel disease. DETAILED DESCRIPTION

[0021] The following is a description of the principles and features of the present invention, and the examples are only used to explain the present invention and are not intended to limit the scope of the present invention. If no specific conditions are specified in the embodiments, the conditions are carried out according to normal conditions or manufacturer recommendations. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be purchased commercially.

[0022] Embodiment 1:

[0023] A composition for ischemic bowel disease comprises ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, dansylvatica glycoside and loganinic acid (the molar ratio is 5:1:1:5:1:1:5).

[0024] A medicine for ischemic bowel disease, comprising the above-mentioned composition for ischemic bowel disease.

[0025] Embodiment 2:

[0026] A composition for ischemic bowel disease comprises ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, dansylvatica glycoside and loganinic acid (the molar ratio is 0.5:0.1:0.1:0.5:0.1:0.1:0.5).

[0027] A medicine for ischemic bowel disease, comprising the above-mentioned composition for ischemic bowel disease.

[0028] Embodiment 3:

[0029] A composition for ischemic bowel disease comprises ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, dansylvatica glycoside and loganinic acid (in a molar ratio of 1:1:1:1:1:1:1:1).

[0030] A medicine for ischemic bowel disease, comprising the above-mentioned composition for ischemic bowel disease.

[0031] Embodiment 4:

[0032] A composition for ischemic bowel disease comprises ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, dansylvatica glycoside and loganinic acid (in a molar ratio of 5:5:20:5:5:5:5).

[0033] A medicine for ischemic bowel disease, comprising the above-mentioned composition for ischemic bowel disease.

[0034] Comparative Example 1:

[0035] A composition for ischemic bowel disease comprises ferulic acid, gentiopicroside and loganinic acid (molar ratio is 5:5:5).

[0036] A medicine for ischemic bowel disease, comprising the above-mentioned composition for ischemic bowel disease.

[0037] Test example

[0038] 1. Evaluation of intestinal mucosal damage

[0039] The compositions prepared in Example 1 and Comparative Example 1 were subjected to an intestinal mucosal injury evaluation experiment by oral gavage. The implementation method was as follows: C57 BL / 6J mice were taken and the intestinal ischemia-reperfusion injury (IIRI) model was used to simulate ischemic bowel disease, i.e., the superior mesenteric artery was clamped for 45 minutes of ischemia and then reperfused for 90 minutes. The mice were divided into a normal group, a model group, an Example 1 group, and a Comparative Example 1 group. After the modeling was completed, the mice were killed and the samples were collected after continuous oral gavage for 7 days, and then H&E staining was performed. The Chiu's score was used to evaluate the damage of the intestinal tissue, and the intestinal adhesion was observed. The results are shown in Table 1.

[0040] Table 1 Effects on intestinal mucosa

[0041]

[0042] Note: *p<0.05 vs. Example 1 group.

[0043] As shown in Table 1, after modeling, the intestinal villi were damaged, a large number of inflammatory cells infiltrated the crypts, and adhesions were formed in the intestine; the composition of Example 1 can significantly reduce intestinal mucosal damage and improve adhesion formation, and reduce Chiu's score. Its therapeutic effect is significantly different from that of the three-component composition of Comparative Example 1. Therefore, the composition of the present invention is irreplaceable, the components of the composition act synergistically, and the drug efficacy is better than that of a single component, and it has a good effect in treating ischemic bowel disease.

[0044] 2. Dose evaluation

[0045] 1. The composition prepared in Example 2 was administered intragastrically to perform an intestinal mucosal injury evaluation experiment. The implementation method was as follows: C57 BL / 6J mice were taken and an intestinal ischemia-reperfusion injury (IIRI) model was used to simulate ischemic bowel disease, that is, the superior mesenteric artery was clamped for 45 minutes of ischemia and then reperfused for 90 minutes. The mice were divided into a normal group, a model group, a low-dose group (ZHWL) of the combination, a medium-dose group (ZHWM) of the combination, and a high-dose group (ZHWH) of the combination. The dosages of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellaria baicalensis glycoside, scutellaria baicalensis glycoside, and loganinic acid in the ZHWL group were 0.5 μmol / kg, 0.1 μmol / kg, 0.1 μmol / kg, 0.5 μmol / kg, 0.1 μmol / kg, 0.1 μmol / kg, and 0.5 μmol / kg, respectively; the dosages of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellaria baicalensis glycoside, and loganinic acid in the ZHWM group were 0.5 μmol / kg, 0.1 μmol / kg, 0.1 μmol / kg, 0.5 μmol / kg, respectively. The dosage of natans, danshin and loganin in mice was 1 μmol / kg, 0.2 μmol / kg, 0.2 μmol / kg, 1 μmol / kg, 0.2 μmol / kg, 0.2 μmol / kg and 1 μmol / kg, respectively. The dosage of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, danshin, danshin and loganin in mice in ZHWH group was 2 μmol / kg, 0.4 μmol / kg, 0.4 μmol / kg, 2 μmol / kg, 0.4 μmol / kg, 0.4 μmol / kg and 2 μmol / kg, respectively. After the model was established, the mice were killed and the samples were collected after continuous oral administration for 7 days. H&E staining was then performed, and Chiu's score was used to evaluate the damage of intestinal tissue. The results are shown in Table 2.

[0046] Table 2 Effects of different doses of the composition on intestinal mucosa

[0047]

[0048] Note: *p<0.05 vs. IIRI group, **p<0.01 vs. IIRI group; # p<0.05vs.ZHWH group, ## p<0.01vs.ZHWH group.

[0049] As shown in Table 2, after the model group was continuously irrigated for 7 days, the results of H&E staining showed that the composition could significantly reduce intestinal mucosal atrophy, intestinal villus shedding, inflammatory infiltration of intestinal epithelial cells, and Chiu's score of intestinal tissue damage.

[0050] 2. Serum samples of the above-mentioned groups of mice were taken and the levels of D-dimer (D2D) and intestinal fat-binding protein (iFABP) were detected strictly according to the operating instructions of the ELISA kit. D2D is closely related to the formation of thrombus in the blood circulation, and iFABP can reflect the severity of villus damage during intestinal ischemia. Both of the above indicators are markers of acute mesenteric ischemia. GraphPad Prism 8.4.0 software was used for analysis and statistical data. The results are shown in Table 3.

[0051] Table 3 Effects of the composition on serum D2D and iFABP levels in mice

[0052]

[0053] Note: *p<0.05vs. model group.

[0054] As shown in Table 3, the levels of D2D and iFABP in the model group increased significantly, while the composition of the present invention can significantly reduce the levels of D2D and iFABP and alleviate acute mesenteric ischemia injury.

[0055] 3. Effects on the expression of FAK / VE-cadherin pathway proteins

[0056] The composition prepared in Example 1 was used to detect the effect on the expression of FAK (focal adhesion kinase) / VE-cadherin (cadherin) pathway proteins. The cells used in the test were human umbilical vein endothelial cells HUVEC (ATCC cell bank, USA), and the FAK phosphorylation inhibitor Y15 (10 μmol / L) (Shanghai Yuanye Biotechnology Co., Ltd.) was used as a control. The test was performed using a conventional Western blot method.

[0057] The specific detection method is as follows: First, establish an OGD / R model, that is, HUVEC cells are placed in a carbon dioxide incubator (containing 5% CO2, 37°C), cultured in DMEM / F-12 1:1 culture medium containing 20% ​​fetal bovine serum, and the medium is changed every 2 days. Cells in the logarithmic growth phase are taken for experiments. The ischemic environment is simulated by a three-gas incubator and oxygen-glucose deprivation. The modeling conditions are: hypoxia for 1 hour and reoxygenation for 4 hours. The results are shown in Table 4.

[0058] Table 4 Effects of the composition on the expression of FAK / VE-cadherin pathway proteins

[0059]

[0060]

[0061] Note: *p<0.05vs.OGD / R group.

[0062] As shown in Table 4, after OGD / R, the p-FAK level was significantly increased, which was 4.44 times that of the normal group, while the combination group, Y15 group and combination + Y15 group were 3.23, 1.64 and 1.83 times of the normal group, respectively, indicating that the combination can significantly reduce the p-FAK level; after OGD / R, the expression of intercellular VE-cadherin was significantly reduced, which was 0.46 times that of the normal group, and the p-β-Catenin level was significantly increased, which was 2.90 times that of the normal group, while the VE-cadherin levels of the combination group, Y15 group and combination + Y15 group were 0.66, 0.76 and 0.70 times that of the normal group, respectively, and the p-β-Catenin levels were 2.29, 1.68 and 1.57 times that of the normal group, respectively; indicating that the combination can significantly increase the expression of VE-cadherin and reduce the p-β-Catenin level.

[0063] IV. Effects on the Expression of MLCK / MLC Pathway Proteins

[0064] The composition prepared in Example 1 was used to detect the effect on the expression of MLCK (myosin light chain kinase) / MLC (myosin light chain) pathway proteins. The cells used in the test were normal human intestinal epithelial cells HIEC-6 (ATCC Cell Bank, USA), and the MLCK inhibitor ML-7 (Shanghai Yuanye Biotechnology Co., Ltd.) (10 μmol / L) was used as a control. The test was performed using a conventional Western blot method.

[0065] The specific detection method is as follows: First, establish an OGD / R model, that is, HIEC-6 cells are placed in a carbon dioxide incubator (containing 5% CO2, 37°C), cultured in DMEM / F-12 1:1 culture medium containing 20% ​​fetal bovine serum, and the medium is changed every 2 days. Cells in the logarithmic growth phase are taken for experiments. The ischemic environment is simulated by a three-gas incubator and oxygen-glucose deprivation. The modeling conditions are: hypoxia for 1 hour and reoxygenation for 4 hours. The results are shown in Table 5.

[0066] Table 5 Effects of the composition on the expression of MLCK / MLC pathway proteins

[0067]

[0068]

[0069] Note: *p<0.05vs.OGD / R group.

[0070] As can be seen from Table 5, after OGD / R, the expression of MLCK increased, which was 2.77 times that of the normal group, while the expression of the combination group, ML-7 group and combination + ML-7 group were 2.32, 1.74 and 1.83 times that of the normal group, respectively, indicating that the composition of the present invention can reduce the expression of MLCK; after OGD / R, the phosphorylation level of MLC was significantly increased, and the expression of tight junction proteins ZO-1 and Occludin was significantly decreased, which were 5.34, 0.29 and 0.46 times that of the normal group, respectively, and the composition of the present invention can protect HIEC-6 intestinal epithelial cells by reducing the expression of MLCK and reducing the level of p-MLC, thereby increasing the expression of ZO-1 and Occludin.

[0071] 5. Effects on the Expression of TGF-β / SMAD3 Pathway Proteins

[0072] The composition prepared in Example 1 was used to detect the effect of the composition on the expression of TGF-β (transforming growth factor-β) / SMAD3 (Smad homolog 3) pathway proteins. The cells used in the test were fibroblasts L929 (ATCC cell bank, USA), and the TGF-β / SMAD3 pathway inhibitor SB431542 (10 μmol / L) (Shanghai Yuanye Biotechnology Co., Ltd.) was used as a control. The test was performed using a conventional Western blot method.

[0073] The implementation method is as follows: first, a TGF-β-induced L929 proliferation and transdifferentiation model was established. L929 cells were placed in a carbon dioxide incubator (containing 5% CO2, 37°C) and cultured in a DMEM / F-12 1:1 culture medium containing 20% ​​fetal bovine serum. The medium was changed every 2 days, and cells in the logarithmic growth phase were taken for the experiment. The modeling conditions were: 2.5 ng / mL TGF-β1 was used to treat L929 cells for 72 hours. The results are shown in Table 6.

[0074] Table 6 Effects of the composition on the expression of TGF-β / SMAD3 pathway proteins

[0075]

[0076]

[0077] Note: *p<0.05vs. TGF-β1 group.

[0078] As shown in Table 6, after TGF-β1 stimulation, the p-SMAD3 level increased by 3.34 times, and the expression of Collagen I and α-SMA increased significantly, which was 1.93 and 1.64 times of the normal group; while the p-SMAD3 levels of the combination group, SB431542 group and combination + SB 431542 group were 1.63, 1.59 and 1.39 times of the normal group, the expression of Collagen I was 1.50, 1.28 and 1.22 times of the normal group, and the expression of α-SMA was 0.89, 1.04 and 1.10 times of the normal group. It shows that the composition of the present invention can significantly inhibit the abnormal proliferation and differentiation of L929 cells by reducing the p-SMAD3 level and reducing the expression of Collagen I and α-SMA.

[0079] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A composition for ischemic bowel disease, characterized in that: Including ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariae maricoside, angelica glycoside and loganinic acid.

2. The composition for ischemic bowel disease according to claim 1, characterized in that: The molar ratio of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, tangyroxylin and loganinic acid is 0.1-5: 0.1-5: 0.1-20: 0.1-5: 0.1-5: 0.1-5: 0.1-5: 0.1-5.

3. The composition for ischemic bowel disease according to claim 1, characterized in that: The molar ratio of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, scutellariae glycoside and loganinic acid is 5:1:1:5:1:1:

5.

4. The composition for ischemic bowel disease according to claim 1, characterized in that: The molar ratio of ferulic acid, ligustilide, angelica lactone A, gentiopicroside, scutellariamarin, dansylvatica glycoside and loganinic acid is 1:1:1:1:1:1:1:

1.

5. Use of the composition for ischemic bowel disease according to any one of claims 1 to 4 in the preparation of a medicament for ischemic bowel disease.

6. A drug for ischemic bowel disease, characterized in that: A composition for ischemic bowel disease comprising the composition according to any one of claims 1 to 4.

7. The drug for ischemic bowel disease according to claim 6, characterized in that: The dosage form of the drug is injection, powder, pill, tablet, microcapsule, soft capsule, film, ointment, tincture, granule and aerosol allowed in pharmacy.

Citation Information

Patent Citations

  • Application of gentiopicroside to medicine for treating inflammatory bowel diseases

    CN102716143A

  • Pharmaceutical composition containing gentiopicroside and its preparation and use

    CN103845354A

  • Ferulic acid drug composition and new application thereof

    CN108714146A

  • Pharmaceutical composition and application thereof in treating ulcerative colitis

    CN114392264A

  • Composition and pharmaceutical preparation thereof

    CN114469934A